Rotavirus immunisation in NICU: a 1-year experience in a UK tertiary neonatal surgical unit postvaccine introduction

Jaques, Siobhan; Ogley, Lucilla; Duffy, Donovan; Kennea, Nigel

doi:10.1136/archdischild-2014-307442

Cited by 11 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In other countries, such as the UK, Australia, or New Zealand, vaccination is not deferred, even if the infant is still hospitalized. Data so far indicate that HRV administration in premature infants is immunogenic and well tolerated [139], in line with observations from clinical trials in more than 1000 infants born at 27-36 weeks gestation [140]. Evidence also continues to accumulate to demonstrate the need and cost-effectiveness of vaccination in preterm infants and other high-risk categories [137].…”

Section: Status Challenges and New Chapters To Exploresupporting

confidence: 56%

Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned

Pereira

Vetter

Standaert

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Rotavirus (RV) disease remains a prominent cause of disease burden in children <5 years of age worldwide. However, implementation of RV vaccination has led to significant reductions in RV mortality, compared to the pre-vaccination era. This review presents 15 years of real-world experience with the oral live-attenuated human RV vaccine (HRV; Rotarix). HRV is currently introduced in ≥80 national immunization programs (NIPs), as 2 doses starting from 6 weeks of age. Areas covered: The clinical development of HRV and post-marketing experience indicating the impact of HRV vaccination on RV disease was reviewed. Expert opinion: In clinical trials, HRV displayed an acceptable safety profile and efficacy against RVgastroenteritis, providing broad protection against heterotypic RV strains by reducing the consequences of severe RV disease in infants. Real-world evidence shows substantial, rapid reduction in the number of RV infections and associated hospitalizations following introduction of HRV in NIPs, regardless of economic setting. Indirect effects against RV disease are also observed, such as herd protection, decrease in nosocomial infections incidence, and a reduction of disease-related societal/ healthcare costs. However, not all countries have implemented RV vaccination. Coverage remains suboptimal and should be improved to maximize the benefits of RV vaccination.

show abstract

Section: Status Challenges and New Chapters To Exploresupporting

confidence: 56%

Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned

Pereira

Vetter

Standaert

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…I løpet av ett år vaksinerte en kirurgisk nyfødtavdeling i London 19 barn. Ingen fikk alvorlige bivirkninger og det ble heller ikke påvist nosokomial smitte (21). I Australia anbefaler man å vaksinere innlagte premature, og i en rapport fra Royal Children´s Hospital i Melbourne ble det vist at man kan oppnå høy vaksinasjonsdekning også hos premature hvis man vaksinerer barn på nyfødtavdelinger (22).…”

Section: Smitterisiko Av Vaksinevirusunclassified

Premature barn bør tidlig vaksineres mot rotavirus

Bruun¹,

Nakstad²,

Greve-Isdahl³

et al. 2019

Tidsskriftet

View full text Add to dashboard Cite

Tone Bruun er spesialist i samfunnsmedisin og overlege ved Avdeling for vaksineforebyggbare sykdommer, Folkehelseinstituttet. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. BRITT NAKSTAD Britt Nakstad er spesialist i barnesykdommer og professor ved Barne-og ungdomsklinikken, Akershus universitetssykehus og Campus Ahus, Universitetet i Oslo. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. MARGRETHE GREVE-ISDAHL Margrethe Greve-Isdahl er spesialist i barnesykdommer og overlege ved Avdeling for vaksineforebyggbare sykdommer, Folkehelseinstituttet. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. HEIDI HOVDE Heidi Hovde er spesialsykepleier ved Avdeling for nyfødte, Barne-og ungdomsklinikken, Akershus universitetssykehus. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. TRULS M. LEEGAARD Truls M. Leegaard er spesialist i medisinsk mikrobiologi, avdelingsoverlege ved Avdeling for mikrobiologi og smittevern, Akershus universitetssykehus og førsteamanuensis ved Institutt for klinisk medisin, Universitetet i Oslo. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. ELMIRA FLEM Elmira Flem er overlege ved Avdeling for infeksjonsepidemiologi og modellering, Folkehelseinstituttet. Forfatteren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.

show abstract

“…However, data from a telephone survey indicated that only 20% of neonatal units in the UK were administering the vaccine at all and in one unit only 38% of those preterm infants eligible received the vaccine in the absence of any contraindications. This led to the development of a RV vaccine administration guidance chart to improve uptake for preterm infants [21,22]. Similar to the UK, the Australian Immunization Handbook suggests that if infection control precautions are maintained, no special dosing requirements are necessary for preterm infants.…”

Section: Variation In Immunization Guidelines For Preterm Infantsmentioning

confidence: 99%